More recently, we elucidated an additional mechanism of tumor suppression mediated by
canonical ephrin - induced EphA2 signaling (Figure 1A), which leads to inhibition of the AKT - mTORC1 oncogenic pathway through interplay of EphA2 with a phosphatase that dephosphorylates the AKT serine / threonine kinase.
Not exact matches
Studies by ours and other groups have shown that a number of EphA2 and EphA3 mutations inactivate Eph receptor
canonical signaling by disrupting
ephrin binding or kinase activity, consistent with a role of
canonical signaling in tumor suppression.
Binding to
ephrin ligands on the surface of neighboring cells induces
canonical signaling involving receptor clustering, autophosphorylation on tyrosine residues, and kinase activity - dependent downstream signaling.
(A) Eph receptor -
ephrin binding at cell - cell contact sites results in the dimerization / clustering of Eph receptor -
ephrin complexes, and initiation of
canonical signals through the receptor cytoplasmic domain.
We found that
canonical signaling by the EphB4 receptor is low in breast cancer cells and that
ephrin - induced stimulation of EphB4 kinase activity inhibits breast cancer cell malignancy in culture and tumor growth in vivo (Figure 1A) through inhibition of the CRK proto - oncogene.